Skip to main content
Top
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

Establishment and evaluation of four different types of patient-derived xenograft models

Authors: Xiaoqian Ji, Siyu Chen, Yanwu Guo, Wende Li, Xiaolong Qi, Han Yang, Sa Xiao, Guang Fang, Jinfang Hu, Chuangyu Wen, Huanliang Liu, Zhen Han, Guangxu Deng, Qingbin Yang, Xiangling Yang, Yuting Xu, Zhihong Peng, Fengping Li, Nvlue Cai, Guoxin Li, Ren Huang

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

Patient-derived xenografts (PDX) have a biologically stable in tumor architecture, drug responsiveness, mutational status and global gene-expression patterns. Numerous PDX models have been established to date, however their thorough characterization regarding the tumor formation and rates of tumor growth in the established models remains a challenging task. Our study aimed to provide more detailed information for establishing the PDX models successfully and effectively.

Methods

We transplanted four different types of solid tumors from 108 Chinese patients, including 21 glioblastoma (GBM), 11 lung cancers (LC), 54 gastric cancers (GC) and 21 colorectal cancers (CRC), and took tumor tissues passaged for three successive generations. Here we report the rate of tumor formation, tumor-forming times, tumor growth curves and mortality of mice in PDX model. We also report H&E staining and immunohistochemistry for HLA-A, CD45, Ki67, GFAP, and CEA protein expression between patient cancer tissues and PDX models.

Results

Tumor formation rate increased significantly in subsequent tumor generations. Also, the survival rates of GC and CRC were remarkably higher than GBM and LC. As for the time required for the formation of tumors, which reflects the tumor growth rate, indicated that tumor growth rate always increased as the generation number increased. The tumor growth curves also illustrate this law. Similarly, the survival rate of PDX mice gradually improved with the increased generation number in GC and CRC. And generally, there was more proliferation (Ki67+) in the PDX models than in the patient tumors, which was in accordance with the results of tumor growth rate. The histological findings confirm similar histological architecture and degrees of differentiation between patient cancer tissues and PDX models with statistical analysis by GraphPad Prism 5.0.

Conclusion

We established four different types of PDX models successfully, and our results add to the current understanding of the establishment of PDX models and may contribute to the extension of application of different types of PDX models.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jin K, Teng L, Shen Y, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12:473–80.CrossRefPubMed Jin K, Teng L, Shen Y, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12:473–80.CrossRefPubMed
2.
3.
go back to reference Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73.CrossRefPubMedPubMedCentral Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73.CrossRefPubMedPubMedCentral
4.
go back to reference Herrmann D, Conway JR, Vennin C, et al. Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. Carcinogenesis. 2014;35:1671–9.CrossRefPubMed Herrmann D, Conway JR, Vennin C, et al. Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. Carcinogenesis. 2014;35:1671–9.CrossRefPubMed
5.
go back to reference Mishra DK, Creighton CJ, Zhang Y, et al. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. Int J Cancer. 2014;134:789–98.CrossRefPubMed Mishra DK, Creighton CJ, Zhang Y, et al. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. Int J Cancer. 2014;134:789–98.CrossRefPubMed
6.
go back to reference Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66:3351–4.CrossRefPubMed Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66:3351–4.CrossRefPubMed
7.
go back to reference Boedigheimer MJ, Freeman DJ, Kiaei P, et al. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. Neoplasia. 2013;15:125–32.CrossRefPubMedPubMedCentral Boedigheimer MJ, Freeman DJ, Kiaei P, et al. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. Neoplasia. 2013;15:125–32.CrossRefPubMedPubMedCentral
8.
go back to reference Damhofer H, Ebbing EA, Steins A, et al. Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. J Transl Med. 2015;13:115.CrossRefPubMedPubMedCentral Damhofer H, Ebbing EA, Steins A, et al. Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. J Transl Med. 2015;13:115.CrossRefPubMedPubMedCentral
9.
go back to reference Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217–21.CrossRefPubMed Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217–21.CrossRefPubMed
10.
go back to reference Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652–61.CrossRefPubMed Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652–61.CrossRefPubMed
11.
go back to reference Kim MP, Evans DB, Wang H, et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670–80.CrossRefPubMedPubMedCentral Kim MP, Evans DB, Wang H, et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670–80.CrossRefPubMedPubMedCentral
12.
go back to reference Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424–31.CrossRefPubMedPubMedCentral Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424–31.CrossRefPubMedPubMedCentral
13.
go back to reference Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10:1311–6.CrossRefPubMedPubMedCentral Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10:1311–6.CrossRefPubMedPubMedCentral
14.
go back to reference Ledford H. US cancer institute overhauls cell lines: veteran cells to be replaced by human tumours grown in mice. Nature. 2016;530(7591):391 (Academic OneFile, Accessed 1 Sept. 2017).CrossRefPubMed Ledford H. US cancer institute overhauls cell lines: veteran cells to be replaced by human tumours grown in mice. Nature. 2016;530(7591):391 (Academic OneFile, Accessed 1 Sept. 2017).CrossRefPubMed
16.
go back to reference Zhang J, Jiang D, Li X, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest. 2014;94:917–26.CrossRefPubMed Zhang J, Jiang D, Li X, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest. 2014;94:917–26.CrossRefPubMed
17.
go back to reference Dieter SM, Giessler KM, Kriegsmann M, et al. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. Int J Cancer. 2017;140:1356–63.CrossRefPubMed Dieter SM, Giessler KM, Kriegsmann M, et al. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. Int J Cancer. 2017;140:1356–63.CrossRefPubMed
18.
go back to reference Zhuang Y, Zhu Y, Wang H, et al. Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy. Br J Med Res. 2017;50(6):e6000. Zhuang Y, Zhu Y, Wang H, et al. Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy. Br J Med Res. 2017;50(6):e6000.
20.
go back to reference Westra WH. Surgical pathology dissection: an illustrated guide. 2nd ed. New York: Springer; 2003.CrossRef Westra WH. Surgical pathology dissection: an illustrated guide. 2nd ed. New York: Springer; 2003.CrossRef
21.
go back to reference Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumors of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumors of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
22.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumors. 7th ed. Chichester: Wiley-Blackwell; 2010. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumors. 7th ed. Chichester: Wiley-Blackwell; 2010.
23.
go back to reference Zhao X, Liu Z, Yu L, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 2012;14:574–83.CrossRefPubMedPubMedCentral Zhao X, Liu Z, Yu L, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 2012;14:574–83.CrossRefPubMedPubMedCentral
24.
go back to reference Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anticancer drug resistance. Proc Natl Acad Sci USA. 2011;108:18708–13.CrossRefPubMedPubMedCentral Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anticancer drug resistance. Proc Natl Acad Sci USA. 2011;108:18708–13.CrossRefPubMedPubMedCentral
25.
go back to reference Jiang Y, Wu Q, Yang X, et al. A method for establishing a patient-derived xenograft model to explore new therapeutic strategies for esophageal squamous cell carcinoma. Oncol Rep. 2016;35:785–92.CrossRefPubMed Jiang Y, Wu Q, Yang X, et al. A method for establishing a patient-derived xenograft model to explore new therapeutic strategies for esophageal squamous cell carcinoma. Oncol Rep. 2016;35:785–92.CrossRefPubMed
26.
go back to reference Van HP, Hulshof MC, Van LJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRef Van HP, Hulshof MC, Van LJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRef
27.
go back to reference Ruhstaller T, Widmer L, Schuller JC, et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009;20:1522–8.CrossRefPubMed Ruhstaller T, Widmer L, Schuller JC, et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009;20:1522–8.CrossRefPubMed
28.
go back to reference Morgan KM, Riedlinger GM, Rosenfeld J, et al. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front Oncol. 2017;7:2.CrossRefPubMedPubMedCentral Morgan KM, Riedlinger GM, Rosenfeld J, et al. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front Oncol. 2017;7:2.CrossRefPubMedPubMedCentral
29.
go back to reference Edwards E, Geng L, Tan J, et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002;62:4671–7.PubMed Edwards E, Geng L, Tan J, et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002;62:4671–7.PubMed
30.
go back to reference Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–9.CrossRefPubMed Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–9.CrossRefPubMed
31.
go back to reference Gerweck LE, Vijayappa S, Kurimasa A, et al. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res. 2006;66:8352–5.CrossRefPubMed Gerweck LE, Vijayappa S, Kurimasa A, et al. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res. 2006;66:8352–5.CrossRefPubMed
32.
go back to reference Ogawa K, Boucher Y, Kashiwagi S, et al. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res. 2007;67:4016–21.CrossRefPubMed Ogawa K, Boucher Y, Kashiwagi S, et al. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res. 2007;67:4016–21.CrossRefPubMed
33.
go back to reference Garcia-Barros M, Thin TH, Maj J, et al. Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res. 2010;70:8179–86.CrossRefPubMedPubMedCentral Garcia-Barros M, Thin TH, Maj J, et al. Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res. 2010;70:8179–86.CrossRefPubMedPubMedCentral
Metadata
Title
Establishment and evaluation of four different types of patient-derived xenograft models
Authors
Xiaoqian Ji
Siyu Chen
Yanwu Guo
Wende Li
Xiaolong Qi
Han Yang
Sa Xiao
Guang Fang
Jinfang Hu
Chuangyu Wen
Huanliang Liu
Zhen Han
Guangxu Deng
Qingbin Yang
Xiangling Yang
Yuting Xu
Zhihong Peng
Fengping Li
Nvlue Cai
Guoxin Li
Ren Huang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0497-4

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine